Towa Pharmaceutical Co., Ltd. (TYO:4553)

Market Cap	194.45B +50.8%
Revenue (ttm)	273.71B +5.4%
Net Income	5.25B -72.3%
EPS	106.65 -72.4%
Shares Out	49.23M
PE Ratio	37.04
Forward PE	9.69
Dividend	80.00 (2.03%)
Ex-Dividend Date	Mar 30, 2026

Volume	143,300
Open	3,860.00
Previous Close	3,860.00
Day's Range	3,815.00 - 3,955.00
52-Week Range	2,764.00 - 4,490.00
Beta	-0.10
Analysts	Buy
Price Target	4,866.67 (+23.21%)
Earnings Date	May 14, 2026

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 4,788
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4553

Financial Performance

In fiscal year 2026, Towa Pharmaceutical's revenue was 273.71 billion, an increase of 5.44% compared to the previous year's 259.59 billion. Earnings were 5.25 billion, a decrease of -72.35%.